How to Get Repatha (Evolocumab) in South Dakota

What Is Repatha and Why Might You Need It

Repatha is a fully human monoclonal antibody that blocks PCSK9, a protein that degrades LDL receptors on liver cells. By blocking PCSK9, evolocumab allows more LDL receptors to remain on the cell surface, which pulls more LDL-cholesterol out of circulation. The FDA approved evolocumab in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond what diet and maximally tolerated statin therapy can achieve 1.

In the landmark FOURIER trial (N=27,564 patients with established cardiovascular disease on statin therapy), evolocumab 140 mg every two weeks or 420 mg monthly reduced LDL-C by 59% from baseline compared with placebo (mean LDL-C fell from 92 mg/dL to 30 mg/dL) and cut the composite endpoint of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization by 15% (HR 0.85 to 95% CI 0.79, 0.92, P<0.001) over a median 2.2 years 2. That translates to a number needed to treat of 67 over the trial period to prevent one major cardiovascular event.

The American College of Cardiology and American Heart Association 2018 Cholesterol Guideline states that in patients with clinical ASCVD on maximally tolerated statin therapy whose LDL-C remains at 70 mg/dL or higher, "a PCSK9 inhibitor may be considered" after discussion of the net benefit, costs, and patient preferences 3. The ACC/AHA threshold guides most South Dakota insurer prior-authorization policies, so knowing these exact numbers before your appointment saves time.

Who Can Prescribe Repatha in South Dakota

Any South Dakota licensed prescriber with Schedule-authority can prescribe evolocumab. That means MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs) are all eligible. South Dakota grants NPs full prescriptive authority under SDCL 36-9A-17, so NPs practicing independently do not need physician supervision to write a Repatha prescription 4. PAs in South Dakota must have a collaboration agreement with a supervising physician per SDCL 36-4A, but that agreement does not prohibit PA-initiated Repatha prescribing within the scope of the collaboration 5.

Cardiologists and lipidologists initiate the majority of Repatha prescriptions nationally, but primary care providers can prescribe it. For patients in rural South Dakota counties without local cardiology access, a telehealth visit with a licensed South Dakota prescriber is a practical path covered in the next section.

The South Dakota Board of Medical and Osteopathic Examiners requires that a valid prescriber-patient relationship exist before controlled or specialty medications are written. For evolocumab, a single synchronous telehealth encounter that includes a review of recent lipid labs, statin history, and cardiac risk generally satisfies that requirement 6.

Telehealth Prescribing for Repatha in South Dakota

South Dakota law permits synchronous audio-video telehealth prescribing of non-controlled specialty medications, including PCSK9 inhibitors. SB 85 (2021) expanded telehealth parity in the state, requiring commercial insurers to reimburse covered telehealth services at the same rate as in-person visits 7. That parity law means a patient can see an in-state telehealth prescriber, get a Repatha prescription, and have that visit covered the same way an office visit would be.

Telehealth works here. A standard telehealth encounter for Repatha typically runs 20 to 30 minutes and covers three items: your lipid history, your statin tolerance record, and your cardiovascular risk documentation. The prescriber will want lab results dated within roughly 90 days sent to them before the visit.

HealthRX connects South Dakota patients with board-certified prescribers licensed in South Dakota who specialize in lipid management and can initiate or continue evolocumab. After the visit, the prescription is sent either to your preferred South Dakota retail pharmacy, a specialty pharmacy (Repatha requires specialty-pharmacy dispensing at most payers), or directly through Amgen's own specialty pharmacy network.

The HealthRX Repatha Access Framework for South Dakota Patients

| Step | Action | Typical Timeframe | |------|--------|-------------------| | 1 | Order or upload fasting lipid panel + LFTs | 1-3 days if using local lab | | 2 | Complete telehealth visit with SD-licensed prescriber | Same day or next day | | 3 | Prescriber submits prior authorization with clinical notes | 1-3 business days | | 4 | Specialty pharmacy ships first injection kit | 3-7 days after PA approval | | 5 | Apply Amgen co-pay card (commercial) or patient-assistance (uninsured) | At or before first fill |

Labs Required Before Starting Repatha in South Dakota

Most South Dakota prescribers and insurance plans require a fasting lipid panel drawn within 90 days of the prior-authorization submission, and nearly all also want a complete metabolic panel (CMP) or at minimum liver function tests (LFTs) to rule out hepatic contraindications 8. A thyroid-stimulating hormone (TSH) test is frequently requested to exclude hypothyroidism as a secondary cause of hypercholesterolemia before PCSK9 therapy is initiated.

Specific numbers matter for prior authorization. Your fasting LDL-C must generally meet a plan-specific threshold, typically 70 mg/dL or higher on maximally tolerated statin therapy for ASCVD patients, or 100 mg/dL or higher for HeFH patients not at ASCVD-level risk. The exact threshold varies by plan, but the ACC/AHA 2018 guideline cutoff of 70 mg/dL for very high-risk ASCVD is cited in most South Dakota commercial-plan PA criteria 3.

Documentation of statin use is equally important. Most payers require evidence of at least one high-intensity statin trial (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg per day) for a minimum of 8 to 12 weeks, unless a documented statin intolerance exists 9. If statin myopathy drove the discontinuation, a creatine kinase (CK) level drawn during the symptomatic period, or a clinical note from the treating physician, can substitute for the lab value.

South Dakota labs that can process fasting lipid panels same-day include Sanford Health outpatient labs (Sioux Falls, Rapid City, Aberdeen) and Avera Medical Group draw sites, as well as national chain options such as Quest Diagnostics and LabCorp, both of which have patient service centers in Sioux Falls and Rapid City 10.

Prior Authorization: What South Dakota Payers Require

Prior authorization for Repatha is not optional with any major South Dakota commercial plan. Sanford Health Plan, Avera Health Plans, Wellmark Blue Cross Blue Shield of South Dakota, and most Medicare Part D plans covering South Dakota residents all require PA before the first fill 11. The good news is that PA approval rates for PCSK9 inhibitors have improved since 2019 following ACC/AHA advocacy.

A complete prior-authorization packet for evolocumab in South Dakota typically needs:

• A completed PA request form from the insurer
• A letter of medical necessity (LMN) from the prescriber specifying diagnosis (ICD-10 code E78.01 for HeFH, E78.00 for pure hypercholesterolemia, or the relevant ASCVD code such as I25.10)
• The most recent fasting lipid panel showing LDL-C at or above the plan threshold
• Documentation of statin therapy trials with doses, durations, and outcomes
• If statin intolerance is claimed: clinical notes or CK labs supporting that claim
• Evidence of dietary counseling or referral (some plans require this per NCEP ATP III precedent) 12

PA decisions typically take 3 to 10 business days. Expedited or urgent-review PA, available when a physician certifies that standard timelines would seriously jeopardize the patient's health, must be decided within 72 hours under federal managed-care rules 13. If the initial PA is denied, the prescriber can appeal. First-level appeals for PCSK9 inhibitors are approved in a meaningful proportion of cases when the appeal letter directly addresses the plan's stated denial reason with the clinical evidence from FOURIER 2.

South Dakota Medicaid and Repatha Coverage

South Dakota Medicaid does not currently cover Repatha for familial hypercholesterolemia or established ASCVD. This is a meaningful barrier for the approximately 116,000 South Dakotans enrolled in Medicaid as of 2024 14. The state's Medicaid formulary excludes PCSK9 inhibitors without a prior-authorization pathway that leads to approval, meaning Medicaid patients must use alternative routes.

Amgen's PCSK9 Patient Assistance Program (Repatha SupportPlus) provides evolocumab at no cost to patients who meet income criteria (generally at or below 600% of the federal poverty level) and who lack adequate insurance coverage. Patients can apply at Amgen's program portal or through the HealthRX care-coordination team. Approval for uninsured or underinsured South Dakotans typically takes 5 to 7 business days after a complete application is submitted 15.

For commercially insured South Dakota patients, Amgen's co-pay assistance card can bring monthly out-of-pocket cost to $0 per month for eligible patients, with the card covering up to the plan's copay or coinsurance 16. Medicare Part D enrollees are not eligible for manufacturer co-pay cards under federal law, but the Extra Help / Low Income Subsidy program may reduce Repatha cost-sharing for qualifying Part D beneficiaries.

Pharmacy Access: Where to Fill Repatha in South Dakota

Repatha is a specialty medication. Most commercial insurance plans require it to be dispensed through a contracted specialty pharmacy rather than a standard retail pharmacy. The major specialty pharmacies serving South Dakota include Accredo (Express Scripts), CVS Specialty, Walgreens Specialty, and Amber Pharmacy (a regional specialty pharmacy with Midwest distribution). Each of these can ship to any South Dakota address with cold-chain packaging 17.

Retail pharmacy dispensing is possible when a plan's formulary allows it, but Repatha's storage requirements (refrigerated at 36 to 46 degrees Fahrenheit, or stored at room temperature up to 77 degrees Fahrenheit for a maximum of 30 days) mean that mail-order specialty distribution is the safer default for rural South Dakota addresses where a package might sit in a hot mailbox or post-office lobby 18.

503A compounding pharmacies in South Dakota are licensed by the South Dakota State Board of Pharmacy and may compound certain medications for patient-specific prescriptions, but FDA-approved biologics like evolocumab cannot legally be compounded under federal law. The FDA prohibits compounding of commercially available biologics under 21 USC 353b and related guidance 19. Any offer of "compounded evolocumab" is not legally or scientifically equivalent to Repatha and should be declined.

Transferring an existing Repatha specialty-pharmacy prescription from another state to a South Dakota specialty pharmacy is straightforward. The receiving pharmacy contacts the original specialty pharmacy to confirm remaining fills, and the prescriber provides an updated prescription if the state license requires it. For patients moving to South Dakota from another state mid-supply, the specialty pharmacy can often ship to a South Dakota address without a prescription transfer for the current supply.

Dosing, Administration, and What to Expect

Evolocumab comes in two dosing regimens approved by the FDA: 140 mg subcutaneous injection every two weeks, or 420 mg subcutaneous injection once monthly. Both regimens produce similar LDL-C reductions of approximately 60% from baseline on top of statin therapy 2. The 420 mg monthly dose uses three 140 mg auto-injector pens or a single 420 mg prefilled cartridge administered with the Pushtronex on-body infusor over about 9 minutes 18.

Most patients learn self-injection in a single training session. Injection sites are the abdomen (at least 2 inches from the navel), the thigh, or the upper arm. The auto-injector is stored in the refrigerator and removed 30 minutes before injection to reach room temperature, which reduces injection-site discomfort.

LDL-C response is detectable within 2 weeks. In FOURIER, the mean LDL-C at 48 weeks was 30 mg/dL in the evolocumab group versus 92 mg/dL in the placebo group 2. A confirmatory lipid panel at 4 to 6 weeks after starting is standard practice to verify response and provide documentation for ongoing PA renewals 3.

Common side effects in FOURIER included nasopharyngitis (10.5% evolocumab vs. 10.3% placebo), upper respiratory tract infection (9.3% vs. 8.0%), and injection-site reactions (2.1% vs. 1.6%) 2. Neurocognitive concerns raised in early post-marketing surveillance were evaluated in the EBBINGHAUS substudy (N=1,204), which found no significant difference in cognitive function between evolocumab and placebo over a median 19 months 20.

Cardiovascular Evidence Supporting Repatha Use

The cardiovascular outcomes data for evolocumab go beyond lipid numbers. FOURIER randomized 27,564 patients with established cardiovascular disease to evolocumab or placebo on top of statin therapy. The primary composite endpoint (CV death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) was reduced from 11.3% in placebo to 9.8% in the evolocumab group (HR 0.85 to 95% CI 0.79, 0.92, P<0.001) 2. When the analysis was restricted to the secondary composite of CV death, MI, and stroke alone, the reduction was 20% (HR 0.80 to 95% CI 0.73, 0.88, P<0.001) 2.

A longer-duration open-label extension called FOURIER-OLE followed 6,635 patients for up to 5 years. Patients originally randomized to evolocumab showed a 15% lower risk of major adverse cardiovascular events compared with those who started evolocumab later, suggesting that earlier and longer therapy produces greater absolute benefit 21. This duration-of-benefit signal has been cited by ACC/AHA writing committees as support for initiating PCSK9 inhibition earlier in the disease course for very high-risk patients 3.

The GLAGOV trial (N=968) used intravascular ultrasound to show that evolocumab produced measurable regression of coronary atherosclerosis over 76 weeks, with 64.3% of evolocumab-treated patients experiencing plaque regression vs. 47.3% on placebo (P<0.001) 22. That plaque-regression data is increasingly used in PA appeal letters when insurers question clinical necessity.

How Long Until You Receive Repatha in South Dakota

After a telehealth visit, the typical timeline from prescription to first injection runs 7 to 21 days for commercially insured South Dakota patients. The longest step is prior authorization, which averages 5 to 10 business days. Specialty pharmacy processing after PA approval adds 2 to 5 business days, including cold-chain shipping to rural South Dakota ZIP codes.

Rural delivery adds one variable. Specialty pharmacies shipping to ZIP codes in western South Dakota (for example, 57701 Rapid City, 57732 Deadwood, 57751 Lead, or 57785 Sturgis) generally use FedEx or UPS overnight or second-day with insulated packaging. Patients in towns near the Montana or Wyoming border should confirm with the specialty pharmacy that summer temperature routing is addressed in the shipment manifest.

Amgen's SupportPlus program can enroll patients in bridge programs that provide a free one-month supply while insurance PA is pending, which closes the gap for most patients 15. Ask the HealthRX care team or the prescribing clinician's office to initiate bridge enrollment at the same time the PA is submitted.

The prescriber's office or HealthRX care coordinator will receive PA status updates and can call for expedited review if day 10 passes without a decision. Under South Dakota Division of Insurance regulations, commercial health plans must process non-urgent PA requests within 15 calendar days 23.

Special Populations: Familial Hypercholesterolemia in South Dakota

Familial hypercholesterolemia affects approximately 1 in 250 people in the general population, meaning an estimated 3,600 South Dakotans have HeFH, though most are undiagnosed 24. HoFH is rarer, affecting roughly 1 in 300,000 people, or about 3 South Dakotans at any given time. For HoFH patients, evolocumab 420 mg monthly is FDA-approved and produces LDL-C reductions of approximately 30% even in patients with essentially no functional LDL receptors 25.

Pediatric use of evolocumab is FDA-approved for patients aged 10 and older with HoFH at 420 mg monthly, based on the HAUSER-OLE extension data 26. South Dakota prescribers treating pediatric HoFH patients should note that PA criteria for pediatric evolocumab often differ from adult criteria and may require documentation from a pediatric cardiologist or lipidologist.

Cascade screening of first-degree relatives is recommended by the American Heart Association whenever a patient is diagnosed with HeFH, because first-degree relatives have a 50% probability of carrying the same mutation 27. South Dakota has no state-funded FH cascade screening program as of 2025, so genetic testing costs must be managed through insurer coverage or direct-pay lab pricing.